Keenova's New Trial Data: A Breakthrough for Chronic Foot Pain Sufferers

DUBLIN, IRELAND – July 08, 2026 – For those living with the daily, debilitating pain of plantar fibromatosis, a walk in the park is anything but. This chronic condition, which causes hard, painful nodules to form on the soles of the feet, has long left patients with few options beyond managing symptoms or undergoing invasive surgery with a high risk of recurrence. Today, that outlook may be changing.

Keenova Therapeutics, a company focused on rare diseases, announced positive results from a pivotal Phase 3 clinical trial for its drug XIAFLEX®. The study showed the treatment significantly reduced pain and improved foot function for patients, marking a potential turning point for a condition that currently has no approved pharmacological treatments. Reading between the lines of the corporate announcement, this isn't just a clinical success; it's a story of targeted science meeting a desperate unmet need, potentially reshaping the lives of thousands while bolstering a company's strategic position in the competitive pharmaceutical landscape.

A Long-Awaited Solution for an Unmet Need

Plantar fibromatosis, also known as Ledderhose disease, is more than just a nuisance. It's a progressive and often painful disorder where excess collagen builds up in the connective tissue supporting the arch of the foot. The resulting nodules can feel like walking on marbles, turning simple acts like standing or walking into a painful ordeal. While classified as a rare disease—affecting fewer than 200,000 people in the U.S.—the burden on those who have it is immense, significantly impairing mobility and quality of life.

Until now, the treatment landscape has been bleak. Patients are often first guided toward conservative measures like custom shoe inserts (orthotics), physical therapy, or over-the-counter pain medications, which primarily manage symptoms rather than addressing the root cause. Steroid injections can provide temporary relief, but the effects often fade, and the nodules return.

"For years, our options have been incredibly limited," explained one podiatrist who treats patients with the condition. "We try to manage the pain and offload pressure, but we can't stop the disease from progressing. When the pain becomes unbearable, the only remaining option is surgery."

However, surgery is a daunting prospect. The most common procedures involve excising the nodules, but recurrence rates are notoriously high, reaching 60% to 100% for a local excision. A more aggressive surgery, removing the entire plantar fascia, carries its own significant risks, including nerve damage, painful scarring, and a potential collapse of the foot's arch, with recurrence still a possibility. The lack of a reliable, non-surgical solution has left a significant gap in care, a gap Keenova now aims to fill.

The Science Behind the Step: How XIAFLEX Works

The promise of XIAFLEX® lies in its elegant biological mechanism. The drug is a targeted enzyme therapy, specifically a combination of collagenases derived from the bacterium Clostridium histolyticum. When injected directly into the fibrous nodules, these enzymes go to work breaking down the specific types of collagen that form the core structure of the unwanted growths. By dissolving this collagen matrix, the treatment aims to reduce the size and stiffness of the nodules, thereby alleviating pain and improving function.

This isn't a new concept for the drug, which is already FDA-approved for two other fibrotic conditions: Dupuytren's contracture, which affects the hands, and Peyronie's disease. This history provides a strong foundation of evidence for its use in targeting abnormal collagen deposits, and the positive Phase 3 results for plantar fibromatosis further validate this approach.

The trial, which enrolled 436 participants, was a double-blind, placebo-controlled study—the gold standard in clinical research. The results were unambiguous. The trial met its primary goal, showing a "statistically significant and clinically meaningful improvement in pain" compared to a placebo. It also succeeded on key secondary measures, demonstrating improved foot function and reduced activity limitation. According to Keenova, the drug's safety profile in the study was consistent with its known profile from other uses, with most side effects being mild and localized.

"With these encouraging results, we intend to submit our application for this indication to the FDA in the fourth quarter of 2026," said Dr. Marek Honczarenko, Keenova's Chief Scientific Officer, in the company's press release. His statement underscores the firm's confidence in the data and its commitment to addressing this "unmet patient need."

A Strategic Step Forward for Keenova

Beyond the clear benefits for patients, this announcement represents a shrewd strategic move for Keenova Therapeutics. As a company that defines its mission as serving patients with "rare or unaddressed conditions," the pursuit of a plantar fibromatosis indication for XIAFLEX® is a perfect fit. It allows the Dublin-headquartered firm to expand the market for an existing, proven asset into a territory with no direct pharmacological competitors.

This is a classic and highly effective lifecycle management strategy. Instead of investing billions into developing a new molecule from scratch, Keenova is leveraging its existing expertise and manufacturing infrastructure for XIAFLEX® to unlock a new revenue stream. The company projects that approximately 300,000 people will see a healthcare provider for the condition in 2028, the year it anticipates launching the product for this new use. Capturing even a fraction of this market, which currently has no approved drugs, could translate into significant financial returns.

"This is precisely the kind of data investors like to see from a company in the rare disease space," commented a healthcare industry analyst. "They've identified a clear unmet need, applied an existing asset with a known safety profile, and produced strong Phase 3 data. It de-risks the development path and creates a clear line of sight to commercialization."

This success reinforces Keenova's position as a specialist in fibrotic disorders and strengthens its diversified portfolio. By building out the XIAFLEX® franchise, the company not only grows its revenue but also solidifies its brand as an innovator capable of finding novel solutions hiding within its existing portfolio.

The Path to Patients' Feet

With the positive data in hand, Keenova's next steps are focused on the regulatory pathway. The planned FDA submission in late 2026 will kick off a formal review process that will likely take most of 2027. Given that plantar fibromatosis is a rare disease, the company may be eligible for Orphan Drug Designation, a status that provides seven years of market exclusivity post-approval—a powerful commercial incentive.

Furthermore, the lack of any existing drug treatments could make XIAFLEX® a candidate for an expedited review process, such as Fast Track or Priority Review, which are designed to get important new medicines to patients sooner. The drug's established safety record from its other approved uses should also help smooth the regulatory journey.

If all goes according to plan, and the FDA agrees with the company's assessment of the data, XIAFLEX® could be available for treating plantar fibromatosis by 2028. For the hundreds of thousands of people struggling with the simple, painful act of walking, this data-driven announcement offers something far more valuable than a market projection: it offers the tangible prospect of taking a step without pain.